, Columnist
Blame the System, not Gilead
Report on Sovaldi pricing is a sign of a broken system.
This article is for subscribers only.
The Senate Committee on Finance report on Gilead’s pricing of its blockbuster hepatitis C drugs Sovaldi and Harvoni is ominous, promising dark revelations of how the firm pursued profit at patient expense. And it's certainly unflattering to Gilead.
But mostly it just describes how pharmaceutical pricing always works. Little wonder the company’s shares are only marginally lower since the report's release earlier this week.